Associations with clinical characteristics and mortality were analyzed using flexible parametric survival models.
INTRODUCTION
Breast cancer is the most common malignancy diagnosed in women worldwide and the number of prevalent cases is increasing due to the overall rise in breast cancer incidence and improved survival rate 1 . As a result of the increased life expectancy, morbidity after a breast cancer diagnosis has become more important from a clinical and public health perspective 2 . Infections are a common complication in breast cancer patients and result from immunosuppression due to treatment or the malignancy itself 3, 4 . Most infections are transient in nature, but their consequences may last longer.
Severe infections, for instance, have been associated with prolonged hospitalization and treatment delay 5, 6 , and are a major cause of future morbidity and mortality 3, 7 .
Despite the considerable impact on patient outcome and health care use, limited data are available on the incidence of serious infections in breast cancer patients. Previous studies have primarily focused on infection-related hospitalizations during periods of chemotherapy-induced neutropenia 8, 9 and data beyond the initial treatment period are scarce. Moreover, breast cancer and its treatment may predispose to infections at certain organ sites, but no studies to date have reported risk estimates for site-specific infections. Also, little is known about the tumor and treatment dependent risk profile and the impact of infection-related hospitalizations on mortality.
In the present study we aimed to assess the risk and prognostic implications of serious infections in breast cancer patients. Using registry-based data, we studied the incidence of infection-related hospitalizations in breast cancer patients as compared to the general female population, overall and by time since diagnosis. We also examined associations with patient, tumor and treatment characteristics as well as the impact of infection-related hospitalizations on overall and breast cancer-specific survival.
PATIENTS AND METHODS

Study population
The Stockholm Breast Cancer Register (SBCR) is a population-based clinical register recording all breast cancer diagnoses occurring in the Swedish counties of Stockholm and Gotland since 1976. The register has more than 95% completeness for women aged less than 75 years at diagnosis and contains detailed information on tumor characteristics and primary breast cancer treatment, as well as routine follow-up information on locoregional recurrence and distant metastasis 10, 11 . For the present study,
we identified all women diagnosed with primary invasive breast cancer at age 25-75 years between 2001 and 2008 (N = 8658). We excluded breast cancer patients with distant metastasis at diagnosis (N = 320), leaving a total of 8338 individuals for the analysis. All patients were linked by the unique personal identity number to the Swedish Inpatient Register, the Swedish Cancer Register, the Swedish Cause of Death Register and the Swedish Emigration Register and follow-up was complete until December 31, 2010. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden. Background rates from the general female population were available through merges with the National Population Register. Since this is a registry-based study, no participant was contacted, and all data were anonymized prior to analysis.
Infectious diseases
Infectious diseases were identified through the Swedish Inpatient Register which has nationwide coverage since 1987 and includes all inpatient hospitalizations in Sweden
12
. Diagnoses were coded according to the relevant International Classification of Diseases (ICD) codes and subdivided into sitespecific groups of infections as described elsewhere 13 ( Supplementary Table S1 ). For the present analysis, we only counted infectious diseases listed as principal diagnosis of hospitalization.
Clinical characteristics
We extracted the following patient, tumor and treatment characteristics from the Stockholm Breast 
17
. For this analysis, we only included breast cancer patients without a history of infectious disease hospitalization prior to diagnosis (N = 7550).
Next, we studied the risk of infection-related hospitalization by patient, tumor and treatment characteristics using FPM which is similar to the Cox proportional hazards model. The main advantage of FPM is that non-proportional hazards can easily be fitted, allowing the effect of exposure variables to vary over time. In all models, time since diagnosis was the underlying time scale and a spline with six knots (five degrees of freedom) was used for the baseline hazard. Proportional hazards assumptions were verified using likelihood ratio tests and in case of non-proportionality timedependent effects were modelled by adding interaction terms with time using a second spline with four knots (three degrees of freedom). We conducted three analyses to assess the impact of clinical characteristics: 1). models adjusting for age and calendar year of diagnosis; 2). grouped models including respectively all patient, tumor and treatment characteristics with additional adjustment for age and calendar year of diagnosis and 3). a multivariable adjusted model including all variables.
Treatment variables were entered as time-fixed variables at diagnosis in all models, as binary timedependent modelling from treatment initiation yielded identical results, due to the short time span between diagnosis and therapy start.
Finally, we studied the impact of infectious disease hospitalization on overall and cause-specific mortality using FPM. Infections were entered as binary time-dependent variable, changing from unexposed at breast cancer diagnosis to exposed at the date of infection hospitalization. For this analysis, we only considered infection-related hospitalizations occurring prior to disease recurrence, as defined above. To examine the impact of infection site, we also modelled the effect for each site separately. All models were adjusted for patient, tumor and treatment characteristics to assess the independent prognostic effect of infection-related hospitalizations. Statistical analyses were carried out using SAS version 9.2 and STATA version 12.0.
RESULTS
Descriptive characteristics of the breast cancer cohort are summarized in Table 1 . Mean age at diagnosis was 57.4 years and the median length of follow-up was 4.9 years. In total, 720 patients experienced an infection-related hospitalization following diagnosis. When comparing rates of sitespecific infections, respiratory infections and sepsis were most frequently reported. The largest group of other infections was unspecified and not classifiable according to organ site (Supplementary Table   S2 ). Table 3 ). Rates for sepsis and skin infections remained increased up to 5 years after diagnosis (SIR = 1.95, 95% CI; 1.37-2.78 and 2.37, 95% CI; 1.60-3.50 respectively), while the excess rate for all other infections was limited to the first year of diagnosis. Figure 1 shows the absolute rates of infection-related hospitalizations by time since diagnosis and organ site. The highest infection rate after diagnosis was found for sepsis and respiratory infections, with a peak rate of respectively 15 and 22 events per 1000 person-years. Absolute rates were lower for skin and gastrointestinal infections, but again with a peak rate in the first year of diagnosis.
Supplementary
Interestingly, a small second peak in skin infection rate was found 2 years after diagnosis. On the other hand, no increased rate was observed for urinary tract infections shortly after diagnosis. showed a consistent pattern with the hazard of infection being higher for more aggressive tumors (larger tumors, high-grade tumor and tumors with axillary lymph node involvement), although the overall HR was only significant for lymph node status after multivariable adjustment (Table 2) .
Associations with patient and tumor characteristics were similar in analyses excluding chemotherapytreated patients (Supplementary Table S4 ).
The strongest treatment effect was observed for chemotherapy and axillary node dissection. An increased hazard was also found in patients undergoing axillary radiotherapy, but this association did not retain significance in multivariable analyses (Table 2 ). More details on chemotherapy treatment were available for 1861 patients, and agent-specific analyses showed a tendency towards a higher risk of infection-related hospitalizations among patients receiving taxanes compared to other chemotherapy agents ( Table 3 ).
The proportional hazards assumption was met for all variables except for age, tumor size, histological grade, axillary lymph node status, chemotherapy and axillary node dissection (Supplementary Table   S5 ). The impact of age varied over time, with older age only having an impact on risk 2 years after diagnosis. While not being significant in overall analysis, large and high-grade tumors were independently associated with an increased risk of infection-related hospitalizations in the first 6 months after diagnosis. Time-dependent analyses further showed that the impact of chemotherapy and axillary lymph node status and dissection, were only short-term, i.e. not detectable 1 year after diagnosis.
We also assessed the impact of infection-related hospitalizations on mortality, after adjustment for patient, tumor and treatment characteristics As shown in Table 4 , patients who were hospitalized with an infection were at increased risk of dying from any cause during follow-up (HR = 1.83, 95% CI = 
DISCUSSION
Hospitalization due to infection is a common cause of hospitalization in breast cancer patients, but estimates of the actual risk and prognostic implications of infection-related hospitalizations are scarce.
This is the first study reporting risk estimates by time since diagnosis and infection site. In total, 720 patients experienced an infection-related hospitalization during a median follow-up of 4.9 years.
Infection rates were highest within the first year of diagnosis, and site-specific risks were most pronounced for sepsis and skin infections compared to rates observed in the general population. Older age at diagnosis, comorbidities, markers of tumor aggressiveness, chemotherapy and axillary node dissection were all independently associated with the risk of infections in multivariable analyses. Our data further indicate that infection-related hospitalizations are an independent predictor of overall and breast cancer specific survival, associations that are mainly driven by respiratory infections and sepsis.
The infectious disease pattern with high relative risks of sepsis and skin infections is in accordance with complications that are commonly seen in breast cancer patients: neutropenia and lymphedema
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.
Chemotherapy-induced neutropenia is a major risk factor for sepsis 19 and lymphedema is one of the strongest risk factors for skin infections
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. Previous studies have shown that the risk of lymphedema remains elevated several years after the breast cancer diagnosis 18, 21 , which is in line with the longterm risk of skin infections found in the present study. The main driver of the long-term sepsis risk is not fully understood, but possible explanations include a suppressed immune system that is further weakened by other breast cancer comorbidities and the use of antibiotics for previous infectious events not requiring hospitalization. For all other infections, excess rates were limited to the first year of diagnosis, except for urinary tract infections for which no time-dependent risk pattern was observed.
The risk of infections after a cancer diagnosis is determined by treatment-related adverse effects, underlying immune deficiencies and associated comorbidities We also observed an independent effect of infection-related hospitalizations on overall and breast cancer specific survival, associations that were mainly driven by respiratory infections and sepsis. , which in turn impacts disease control. However, the observed association between respiratory infections and breast cancer death can also be interpreted as early symptom of lung metastases. Since the impact of infection-related hospitalizations on breast cancer death was observed for respiratory infections solely, this is also a plausible explanation for this specific outcome.
Strengths of our study are the population-based design and linkage to register-based data which . We further tried to minimize the impact of potential misclassification by analyzing main diagnoses only. Also, we were unable to study risk factors per organ site, due to the limited number of incident events per site-specific infection. Finally, we could not investigate the impact of immunomodulatory therapies such as Traztuzumab for human epidermal growth factor receptor 2 (HER2) positive cancers, as this therapy was not routinely prescribed during the study period.
From a clinical perspective, the adverse effect of treatment including chemotherapy needs to be balanced against the survival benefit, with recent trial data showing a ~30% reduction in 10-year mortality with even moderate chemotherapy regimens
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. Moreover, short-term prevention of infection-related hospitalizations is challenging in an immunocomprised host, although several strategies have been proposed for infectious disease prevention in chemotherapy-treated patients including immunizations and simple hygiene measures 37, 38 . Apart from chemotherapy, we identified several patient, tumor and treatment-related risk factors, and this information may aid in the development of tailored, preventive strategies. Since more patients survive breast cancer today, the number of prevalent cases with infectious complications will increase. Given the impact of infectionrelated hospitalizations on morbidity, mortality, and health care associated costs, more efforts are needed to reduce the burden of this complication.
Collectively, our study shows that a significant number of breast cancer patients are hospitalized with an infection following diagnosis, which in turn predicts poor prognosis. The excess rate of infectionrelated hospitalization is highest within the first year of diagnosis, with site-specific risks being most pronounced for sepsis and skin infections. We further demonstrate that the risk profile for infectionrelated hospitalizations is multifactorial, with patient, tumor and treatment characteristics contributing to risk in a time-dependent manner. In light of the growing number of prevalent breast cancer cases, this complication deserves more clinical awareness and investigation. Abbreviations: HR = hazard ratio; CI = confidence interval. a Hazard ratios as estimated from flexible parametric survival models with time since diagnosis as underlying time scale. Model 1: adjusted for age and calendar year of diagnosis; Model 2: grouped models including respectively all patient, tumor and treatment characteristics with additional adjustment for age and calendar year of diagnosis; Model 3: multivariable adjusted including all variables listed in the table and calendar year of diagnosis. Missingness on individual variables < 5%, except for histological grade (39.3%, N = 3279), which was included in the Stockholm-Gotland Breast Cancer Register from 2004 onwards and ER status (7.3%, N = 609) and PR status (8.9%, N = 743).
b No. of dissected lymph nodes refers to the total number of lymph nodes dissected at sentinel node procedure and axillary surgery.
c The proportional hazards assumption was not met for age at diagnosis, tumor size, histological grade, no. of positive lymph nodes, chemotherapy and no. of dissected lymph nodes. Abbreviations: HR = hazard ratio; CI = confidence interval. a Hazard ratios are derived from flexible parametric survival models with infection-related hospitalization as time-varying exposure and time since diagnosis as underlying time scale. All hazard ratios are adjusted for patient (age at diagnosis, CCI, infectious disease history), tumor (size, grade, ER status, PR status, no. of positive lymph nodes) and treatment-related factors (endocrine therapy, chemotherapy, radiotherapy, surgery and no. of dissected lymph nodes) and calendar year of diagnosis. 
